Phoophiboon, Vorakamol https://orcid.org/0000-0001-5461-9448
Rodrigues, Antenor
Ko, Matthew
Menga, Luca S.
Vieira, Fernando
Docci, Mattia
Sharifi, Kiana
Schreiber, Annia
Sousa, Mayson L. A.
Goffi, Alberto
Rigamonti, Andrea
Brochard, Laurent
Funding for this research was provided by:
Physicians' Services Incorporated Foundation (23-26)
Article History
Received: 23 November 2025
Accepted: 16 January 2026
First Online: 25 February 2026
Declarations
:
: The Unity Health Toronto Research Ethics Board (REB) at St. Michael’s Hospital approved the study protocol [#23-231]. Informed consent was obtained directly from patients or their substitute decision-makers (SDMs) and deferred consent was used when the patient was not competent and SDM was not available.
: Not applicable.
: VP was granted partially by Physician’s Services Incorporated (PSI) Foundation (No.23-26), Ontario, Canada for this work. LB reports a relationship (funding grants) with Medtronic, Drager Medical GmbH, SenTec Inc, Phillips and Fisher & Paykel healthcare Inc. FV is currently employed by Fisher & Paykel Healthcare. Others declare no competing interests relevant to this work.
: The authors declare that they have no competing interests.